Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
A distinguished panel of clinical and policy experts gathered by Novo Nordisk recently convened in Washington, D.C. to explore solutions to address the exponential growth of diabetes in America. The universal theme from the renowned …
A distinguished panel of clinical and policy experts gathered by Novo Nordisk recently convened in Washington, D.C. to explore solutions to address the exponential growth of diabetes in America. The universal theme from the renowned …
WASHINGTON D.C. - Most patients with acromegaly who are switched to the long-acting somatostatin analogue lanreotide (SomatulineR Depot) injection from initial treatment with octreotide cite a preference for lanreotide as their future therapy, according to …
“The prices of hundreds of brand-name drugs are about to be cut 4%, and millions of Americans may soon receive a check in the mail as compensation for having overpaid for their prescriptions,” but “the …
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company’s …
Medivation, Inc. (Nasdaq: MDVN) announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer’s disease. …
Neurim Pharmaceuticals presented the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the …
Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600 and 600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark …
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that Patrick Iversen, Ph.D., Senior Vice President of Strategic Alliances, will present at the upcoming 7th Annual Biodefense Vaccines & Therapeutics conference taking place …
An analysis of the latest peptide genomic data for the H1N1 influenza virus indicates that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data on PubMed of …
Cephalon, Inc. (Nasdaq: CEPH) presented results from a pivotal trial that showed NUVIGIL(R) (armodafinil) Tablets [C-IV] significantly improved wakefulness in people with excessive sleepiness associated with jet lag disorder. These phase three data were …
InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose …
MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has been …
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application …
A new survey released shows that 3 out of 4 (75%) adults with high blood pressure are not at all familiar with the role of the renin system(1) — a key regulator of blood pressure …
Roche announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This …
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, …
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that Isis’ antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association’s (ADA) 69th Scientific Sessions in New …
Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) …
United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved …
| DJIA | 10320.10 | ||
| NASDAQ | 2200.01 | ||
| S&P 500 | 1090.10 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Jun | ||||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||
